Figure 5 | Scientific Reports

Figure 5

From: Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease

Figure 5

Relative binding affinity of various peptide motifs to the FXR LBD in the presence of avermectin analogues as determined by peptide competition assays.

Various unlabeled peptides (20 μM) are used to compete off the binding of the biotin-labeled SRC2-3 LXXLL motif to FXR LBD in response to 1 μM ivermectin, abamectin, doramectin, or 0.5 μM GW4064, respectively. Values are the means ± SEM of three independent experiments. Sequences of peptides used in the AlphaScreen assays are as described previously28.

Back to article page